
ClearPoint Neuro (NASDAQ:CLPT) reported record first-quarter 2026 revenue and reaffirmed its full-year outlook, as management highlighted growth in its legacy neurosurgical device business and early contributions from the recently acquired IRRAflow product line.
Chief Executive Officer Joe Burnett said the company generated $12.1 million in revenue for the quarter, driven by what he described as 25% organic devices growth across drug delivery cannulas, navigation disposables, laser ablation applicators, capital systems and software. Including the IRRAflow assets acquired from IRRAS Holdings, Burnett said companywide growth reached 43%.